Die SURMOUNT-1-Studie [8] umfasste 2539 bergewichtige Probanden, die ber 72 Wochen 5, 10 oder 15 mg Tirzepatid im Vergleich zu Placebo erhielten
Semaglutide is the top driver for prescription demand both in hospitals and retail pharmacies
this is a class-level precaution rather than an established risk specific to retatrutide
By making healthy lifestyle changes in a medical setting with supportive resources like 1:1 virtual coaching, you can regain control of your health and feel like yourself again
Preclinical research in animal models has identified GLP-1 receptors in synovial tissue, cartilage, and bone, suggesting potential for direct effects on joint structures
In addition to SGLT2 inhibitors and GLP-1 receptor agonists, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated significant cardiovascular and kidney-protective effects in people with type 2 diabetes mellitus and CKD or HF [129-132]